Header Logo

Connection

WILLIAM WONG to Bevacizumab

Back to Details
This is a "connection" page, showing publications WILLIAM WONG has written about Bevacizumab.
WILLIAM WONG
Connection Strength
0.031
Bevacizumab
  1. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. J Oncol Pract. 2016 06; 12(6):e710-23.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.